UOC
FLXN

UBS O'Connor’s Flexion Therapeutics, Inc. FLXN Stock Holding History

UBS O'Connor’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-75,000
Closed -$1.12M – 521
2016
Q2 		$1.12M Sell
75,000
-84,610
-53% -$1.06M 0.02% 286
2016
Q1 		$1.47M Buy
+159,610
New +$1.94M 0.01% 342
2015
Q1 		– Sell
-34,250
Closed -$692K – 905
2014
Q4 		$692K Buy
+34,250
New +$621K 0.01% 381

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

UBS O'Connor's FLXN Position: Q3 2016 in Review

UBS O'Connor sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2016, closing a stake of 75,000 shares — an estimated $1.12M sold.

UBS O'Connor first reported a position in FLXN in Q4 2014 and held it in 3 quarters. The position peaked at $1.47M in Q1 2016. 84 funds tracked by Wall St. Rank hold FLXN as of Q3 2016.

  • UBS O'Connor reported no remaining Flexion Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 75,000 Flexion Therapeutics, Inc. shares in Q3 2016, an estimated $1.12M.
  • UBS O'Connor first reported a position in Flexion Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • UBS O'Connor's Flexion Therapeutics, Inc. position peaked at $1.47M in Q1 2016.
  • 84 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.